Key result
Cloned diabetogenic CVB4E2 VP1 protein achieves ~96% sequence identity and successful expression in E. coli.
Why the study?
The study aimed to clone the VP1 gene of human coxsackievirus B4 strain E2 in a prokaryotic plasmid expression vector and compare it with structural capsid proteins of the same strain using bioinformatic tools.
The successful production and characterization of the CVB4E2 rVP1 protein establishes a foundational methodology and resource for the future development of subunit vaccines and immunodiagnostic reagents.
rVP1 cloning supplies a characterized antigen for preclinical testing; leaves open human vaccine translation for CVB4-associated diabetes.
The aim of the present study was, first, to clone the VP1 gene of the human coxsackievirus B4 strain E2 (CVB4E2) in the prokaryotic pUC19 plasmid expression vector then to compare it with the structural capsid proteins of the same strain using bioinformatic tools. PCR colony amplification followed through a restriction digestion analysis and sequencing process which affirmed the success of the cloning process. SDS-PAGE and Western Blotting were used to characterize the purified recombinant viral protein expressed in bacteria cells. The BLASTN tool revealed that the nucleotide sequence of the recombinant VP1 (rVP1) expressed by pUC19 highly matched the target nucleotide sequence of the diabetogenic CVB4E2 strain. Secondary structure and three-dimension structure prediction suggested that rVP1, such as wild-type VP1, is chiefly composed of random coils and a high percentage of exposed amino acids. Linear B-cell epitope prediction showed that several antigenic epitopes are likely present in rVP1 and CVB4E2 VP1 capsid protein. Additionally, phosphorylation site prediction revealed that both proteins may affect the signal transduction of host cells and can be involved in virus virulence. The present work highlights the usefulness of cloning and bioinformatics characterizations for gene investigation. Furthermore, the collected data are helpful for future experimental research related to the development of immunodiagnostic reagents and subunit vaccines based on the expression of immunogenic viral capsid proteins.
No takes yet. Share an insight, caveat, or question.
Hassine et al. (2023) studied this question. Cloning and expression of CVB4E2 VP1 gene was evaluated on Successful cloning, expression, and bioinformatic characterization of rVP1. The VP1 gene of the diabetogenic CVB4E2 strain was successfully cloned, expressed in E. coli, and bioinformatically characterized, demonstrating 96% sequence identity with the target strain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: